Sign up today to learn more about HeartFlow stock
Medical Technology Company
About HeartFlow Stock
HeartFlow is a medical technology company that provides non-invasive coronary artery disease detection services. The company's main product is HeartFlow FFRCT Analysis, which aims to help a physician evaluate whether a patient has significant coronary artery disease. HeartFlow FFRCT Analysis uses a CT scan that is ordered by a physician to generated a 3D model of the patient's coronary arteries. The analysis aims to calculate the amount of blockage in the arteries and the limited blood flow.
The company additionally offers HeartFlow Planner which allows physicians to model treatment strategies for coronary artery disease.
The company is currently operating with business as usual, albeit with smaller, isolated teams. HeartFlow is allowing for hospitals to divert resources toward COVID-19 by letting algorithms replace invasive procedures like angiograms.
Christopher K. Zarins and Charles Anthony Taylor founded Cardiovascular Simulation in 2007 that became HeartFlow in May 2009. The company is headquartered in Redwood City, California.
Chief Executive Officer
Chief Technology Officer
Charles Anthony Taylor
BioWorld - Jan, 31 2020
businesswire - Sep, 12 2019
bioportfolio - May, 23 2019
computerworlduk - Feb, 21 2019
massdevice - Feb, 8 2019